| abstract |
The present invention provides flaviviruses and methods for making and using these vaccines. Flaviviruses comprising one or more hinge region mutations that reduce the pro-organism of flaviviruses. In one example of a chimeric flavivirus, the chimera includes a second flavivirus virus or dengue virus comprising capsids and nonstructural proteins of the first flavivirus and an envelope protein mutation that reduces the pro-organism of the chimeric flavivirus. Of pre-membrane and envelope protein. In the case of dengue virus, the mutation can be, for example, a lysine at dengue envelope amino acid 202 or 204. This amino acid can be substituted with, for example, arginine. [Selection figure] None |